GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. 11:35:10 2024-07-24 am EDT 5-day change 1st Jan Change
1,510.00 GBX +0.03% Intraday chart for GSK plc -1.21% +4.12%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
GSK Says Health Canada Approves Jemperli as Endometrial Cancer Treatment MT
GSK: QUEBEC'S COMMITTEE ON IMMUNIZATION RECOMMENDS USE OF RSV VA… RE
GSK : Receives a Buy rating from Jefferies ZD
GSK Unit Says Dovato 'Non-Inferior' to Biktarvy in Phase 4 HIV Study MT
GSK: licensing agreement with Touchlight CF
GSK announces promising trial data for ViiV Healthcare HIV drugs AN
SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports CI
GSK: ViiV Healthcare's Dovato Shows Noninferiority, Lower Weight Gain in Late-stage HIV-1 Treatment Trial MT
GSK Unit's New Investigational Drug Shows Antiviral Activity against Integrase Resistance MT
GSK Unit's Late-stage Study Shows HIV Prevention Drug's Efficacy, Safety in Pregnant Patients MT
GSK - VIIV HEALTHCARE EARLY DATA SHOWING ANTIVIRAL ACTIVITY AGAI… RE
GSK: VIV'S FINDINGS SHOW MATERNAL AND PREGNANCY OUTCOMES WITH AP… RE
GSK: VIIV HEALTHCARE ANNOUNCES POSITIVE NEW DATA FOR APRETUDE US… RE
GSK- DTG/3TC-TREATED INDIVIDUALS HAD SIGNIFICANTLY LESS WEIGHT G… RE
GSK: VIIV HEALTHCARE'S POSITIVE DATA DEMONSTRATING 2-DRUG REGIME… RE
European Equities Close Lower Friday; Inflation Expectations Unchanged in ECB Survey MT
GSK's Marketing Authorization Application for Blenrep Combinations Accepted for Review in EU MT
GSK: marketing authorization from the EMA CF
GSK plc Announces Blenrep EMA Filing Acceptance CI
Market hiccup: LSE glitch leaves traders hanging, FTSE 100 stutters Our Logo
GSK's Multiple Myeloma Combination Therapies Accepted for Review in EU MT
Stocks suffer on underwhelming local data AN
GSK drug for multiple myeloma accepted for European regulatory review AN
GSK: BLENREP (BELANTAMAB MAFODOTIN) COMBINATIONS IN MULTIPLE MYE… RE
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading MT
Chart GSK plc
More charts
Logo GSK plc
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Employees
70,212
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
15.10GBP
Average target price
19.85GBP
Spread / Average Target
+31.47%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. GSK Starts Appeal Process Against Delaware Court Decision Allowing Expert Testimonies in Zantac Litigation